SFY0 Stock Chart & Stats
€2.42
€0.00(0.00%)
At close: 4:00 PM EDT
€2.42
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.42 - €2.42
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€10.00M
Enterprise Value€3.70
Total Cash (Recent Filing)€11.34M
Total Debt (Recent Filing)€3.55M
Price to Earnings (P/E)―
Beta0.00
Next Earnings
Nov 17, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding45,892,670
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.86Price Target Upside-64.53% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.19
Revenue Forecast (FY)€25.25M
Bulls Say, Bears Say
Bulls Say
Clinical Development MomentumVIRAGE2 converts earlier survival observations into a focused clinical development step, with regulators encouraging more frequent dosing. Progress toward a potential pivotal trial could strengthen the lead asset, although efficacy remains unproven.
Differentiated Oncology PlatformVCN-01’s proposed stroma-degrading and immune-modulating mechanism may differentiate it in refractory solid tumors. The translational findings support further combination development and could improve partnering potential if replicated.
Modest Financial LeverageModest leverage limits interest and refinancing pressure relative to highly indebted peers, while positive equity provides some financial flexibility. This cushion is helpful for clinical execution, though continued losses could reduce it materially.
Bears Say
Minimal Commercial TractionTheriva has not demonstrated scalable commercial traction, leaving the business dependent on clinical milestones rather than recurring product sales. This increases execution risk and makes future funding or partnering critical to advancing the pipeline.
Persistent Losses And Cash BurnOngoing losses translate into substantial cash consumption, indicating that development operations cannot currently fund themselves. Continued negative cash flow creates recurring financing needs and leaves results highly dependent on successful trial outcomes.
Dilution And Funding OverhangExpanded equity capacity and potential warrant exercises may provide financing flexibility but create meaningful dilution risk. The delayed warrant vote also adds procedural uncertainty around the company’s future capital structure.
Theriva Biologics News
SFY0 FAQ
What was Theriva Biologics’s price range in the past 12 months?
Theriva Biologics lowest stock price was €2.42 and its highest was €2.42 in the past 12 months.
What is Theriva Biologics’s market cap?
Theriva Biologics’s market cap is €10.00M.
When is Theriva Biologics’s upcoming earnings report date?
Theriva Biologics’s upcoming earnings report date is Nov 17, 2026 which is in 80 days.
How were Theriva Biologics’s earnings last quarter?
Theriva Biologics released its earnings results on Aug 11, 2026. The company reported -€0.06 earnings per share for the quarter, missing the consensus estimate of -€0.047 by -€0.013.
Is Theriva Biologics overvalued?
According to Wall Street analysts Theriva Biologics’s price is currently Overvalued.
Does Theriva Biologics pay dividends?
Theriva Biologics does not currently pay dividends.
What is Theriva Biologics’s EPS estimate?
Theriva Biologics’s EPS estimate is -0.06.
How many shares outstanding does Theriva Biologics have?
Theriva Biologics has 45,892,670 shares outstanding.
What happened to Theriva Biologics’s price movement after its last earnings report?
Theriva Biologics reported an EPS of -€0.06 in its last earnings report, missing expectations of -€0.047. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Theriva Biologics?
Currently, no hedge funds are holding shares in DE:SFY0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Theriva Biologics
Theriva Biologics Inc. is a clinical-stage biotechnology firm dedicated to developing novel treatments for conditions with significant unmet medical needs. The company's pipeline features several promising candidates, including SYN-004, which is engineered to break down commonly used intravenous beta-lactam antibiotics in the gastrointestinal tract. This degradation aims to avert microbiome damage, Clostridioides difficile infection (CDI), the overgrowth of harmful organisms, the rise of antimicrobial resistance (AMR), and acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplants. Another key investigational therapy is SYN-020, an orally administered recombinant formulation of intestinal alkaline phosphatase, designed to address both localized gastrointestinal and systemic diseases. Additionally, Theriva Biologics is advancing VCN-01 for the treatment of various cancers, specifically pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. Its broader clinical-stage portfolio includes SYN-006, intended to prevent aGVHD and infections caused by carbapenem-resistant enterococci; SYN-007, aimed at preventing antibiotic-associated diarrhea linked to oral beta-lactam antibiotics; SYN-005, for both the prevention and treatment of pertussis; and VCN-11, another cancer-focused therapy. The company collaborates with institutions such as Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. Furthermore, a clinical trial agreement with Washington University School of Medicine in St. Louis is in place to conduct a Phase 1b/2a clinical trial for SYN-004. Formerly known as Synthetic Biologics, Inc., the company rebranded as Theriva Biologics Inc. in October 2022 and is headquartered in Rockville, Maryland.
SFY0 Stock 12 Month Forecast
Average Price Target
€0.86
▼(-64.53% Downside)